
biomed devic servic
driver start posit well
guidanc buy pt
bottom line reiter buy rate follow fda approv system
morn host confer call discuss approv overal
manag commentari reinforc posit sentiment system
approv abil off-set competit pressur new entrant libr
abbott guardian connect
earli approv launch support upsid estim manag note
plan launch system us month sooner
previou expect late june launch ada expect launch like
come late april posit compani earli commentari
result call earli may estim current assum launch us
offer potenti upsid estim primarili new patient growth
earlier launch activ set well momentum
season strong back-half year ou perspect european launch
expect ce mark approv
price launch strategi focu given hard shut-off day biggest
take-away call opinion fact new fda special criteria
mandat hard sensor shut-off base product label case
day dilig suggest exist patient stretch sensor far
beyond approv wear time like much model say
day transit hard stop day therefor potenti increas
real-world sensor util sensor per year add fact
potenti bill increment day label situat
loyal user may face increas pocket cost -- someth
consist screen top concern survey work -- focal point
commerci plan libr manag laid formal commerci
plan howev caution investor factor increas price
util model compani consist reiter focu patient
cost product satisfact still work potenti scenario
price reimburs standpoint yet made chang
forward estim said expect minimum use launch
way protect futur price eros libre/guardian potenti re-engag
payor access pharmaci channel
system offer meaning enhanc eas use accuraci reliabl
integr aid system remind bring sever major chang
includ simplifi applic extend sensor wear time day vs
previous updat hardwar compon includ new receiv thinner/
lighter transmitt reduc on-bodi size/form-factor reduc medic
interfer particularli acetaminophen importantli least competit
come factori calibr thu elimin need daili fingerstick test altogeth
vs daili calibr test
continu next page
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
fda new icgm classif detail limit posit implic
product pipelin previous announc fda approv via
de novo pathway integr continu glucos monitor system
icgm note system approv stand-alone use also part
integr diabet manag solut autom insulin dose aid
system conjunct approv fda announc establish
special control criteria icgm system allow futur gener icgm
product pursu clearanc pathway special control outlin
requir accuraci reliabl clinic relev study/data requir
 criteria manag describ rigor high bar ensur safeti
efficaci futur system mind potenti significantli reduc
regulatori burden futur product approv assum product meet
expect high-bar accuracy/reli potenti
usher robust period product innov diabet space
believ de novo pathway posit implic product
pipelin help expedit approval/launch meaning new featur given
compani verili product base sensor see potenti
expedit path market note still remain event continu
look fda full special control criteria releas time unclear better
understand impact may competit dynam us cgm
although adjust estim increas price target
account increas high-growth comp group multipl high-
growth med-tech comp group sale growth current trade mean
ev/sal multipl estim revenu base valuat
ev/sal multipl appli revenu estim price
target assum cash debt share outstand
figur matrix discount rate impli share price target
buy unchang target price march
biomed devic servic
discount comp ev/sal multipl price metric use ev/sal valuat growth medic devic ev/sal multipl sale share outstand figur dexcom incom statement
canaccord genuiti estim compani report detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price march
biomed devic servic
canaccord genuiti estim compani report compani report
buy unchang target price march
biomed devic servic
